Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：21

作者：

Schipilliti, Francesca Matilde ^{[1
]}

Drittone, Denise ^{[1
]}

Mazzuca, Federica ^{[2
]}

La Forgia, Daniele ^{[3
]}

Guven, Deniz Can ^{[4
]}

Rizzo, Alessandro ^{[3
]}

机构：

[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy

[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy

[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy

[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye

来源：

HELIYON | 2024年 / 10卷 / 07期

关键词：

Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;

D O I：

10.1016/j.heliyon.2024.e28385

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.

引用

页数：7

共 36 条

[1] Oncogene-mediated metabolic gene signature predicts breast cancer outcome [J].

Aslan, Merve ;

Hsu, En-Chi ;

Garcia-Marques, Fernando J. ;

Bermudez, Abel ;

Liu, Shiqin ;

Shen, Michelle ;

West, Meredith ;

Zhang, Chiyuan Amy ;

Rice, Meghan A. ;

Brooks, James D. ;

West, Robert ;

Pitteri, Sharon J. ;

Gyorffy, Balazs ;

Stoyanova, Tanya .

NPJ BREAST CANCER, 2021, 7 (01)

[2] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial [J].

Bardia, A. ;

Messersmith, W. A. ;

Kio, E. A. ;

Berlin, J. D. ;

Vahdat, L. ;

Masters, G. A. ;

Moroose, R. ;

Santin, A. D. ;

Kalinsky, K. ;

Picozzi, V ;

O'Shaughnessy, J. ;

Gray, J. E. ;

Komiya, T. ;

Lang, J. M. ;

Chang, J. C. ;

Starodub, A. ;

Goldenberg, D. M. ;

Sharkey, R. M. ;

Maliakal, P. ;

Hong, Q. ;

Wegener, W. A. ;

Goswami, T. ;

Ocean, A. J. .

ANNALS OF ONCOLOGY, 2021, 32 (06) :746-756

[3] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer [J].

Bardia, A. ;

Hurvitz, S. A. ;

Tolaney, S. M. ;

Loirat, D. ;

Punie, K. ;

Oliveira, M. ;

Brufsky, A. ;

Sardesai, S. D. ;

Kalinsky, K. ;

Zelnak, A. B. ;

Weaver, R. ;

Traina, T. ;

Dalenc, F. ;

Aftimos, P. ;

Lynce, F. ;

Diab, S. ;

Cortes, J. ;

O'Shaughnessy, J. ;

Dieras, V ;

Ferrario, C. ;

Schmid, P. ;

Carey, L. A. ;

Gianni, L. ;

Piccart, M. J. ;

Loibl, S. ;

Goldenberg, D. M. ;

Hong, Q. ;

Olivo, M. S. ;

Itri, L. M. ;

Rugo, H. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16) :1529-1541

[4] Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer [J].

Cortes, J. ;

Kim, S. -B ;

Chung, W. -P ;

Im, S. -A ;

Park, Y. H. ;

Hegg, R. ;

Kim, M. H. ;

Tseng, L. -M ;

Petry, V ;

Chung, C. -F ;

Iwata, H. ;

Hamilton, E. ;

Curigliano, G. ;

Xu, B. ;

Huang, C. -S ;

Kim, J. H. ;

Chiu, J. W. Y. ;

Pedrini, J. L. ;

Lee, C. ;

Liu, Y. ;

Cathcart, J. ;

Bako, E. ;

Verma, S. ;

Hurvitz, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (12) :1143-1154

[5] Evolving Strategies for Target Selection for Antibody-Drug Conjugates [J].

Damelin, Marc ;

Zhong, Wenyan ;

Myers, Jeremy ;

Sapra, Puja .

PHARMACEUTICAL RESEARCH, 2015, 32 (11) :3494-3507

[6] Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial [J].

Dieras, Veronique ;

Miles, David ;

Verma, Sunil ;

Pegram, Mark ;

Welslau, Manfred ;

Baselga, Jose ;

Krop, Ian E. ;

Blackwell, Kim ;

Hoersch, Silke ;

Xu, Jin ;

Green, Marjorie ;

Gianni, Luca .

LANCET ONCOLOGY, 2017, 18 (06) :732-742

[7] Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer [J].

Fang, Y. J. ;

Lu, Z. H. ;

Wang, G. Q. ;

Pan, Z. Z. ;

Zhou, Z. W. ;

Yun, J. P. ;

Zhang, M. F. ;

Wan, D. S. .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2009, 24 (08) :875-884

[8] Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions [J].

Ferraro, Emanuela ;

Drago, Joshua Z. ;

Modi, Shanu .

BREAST CANCER RESEARCH, 2021, 23 (01)

[9] Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon [J].

Furlanetto, Jenny ;

Marme, Frederik ;

Loibl, Sibylle .

FUTURE ONCOLOGY, 2022, 18 (28) :3199-3215

[10] Bystander effect of antibody-drug conjugates: fact or fiction? [J].

Giugliano, Federica ;

Corti, Chiara ;

Tarantino, Paolo ;

Michelini, Flavia ;

Curigliano, Giuseppe .

CURRENT ONCOLOGY REPORTS, 2022, 24 (07) :809-817

← 1 2 3 4 →